Paracetamol + metoclopramide


Concise Prescribing Info
Indications/Uses
Migraine.
Dosage/Direction for Use
Adult: PO Per tab contains paracetamol 500 mg and metoclopramide 5 mg: Initial: 2 tablets at first warning of an attack. May repeat doses at 4 hrly intervals. Max: 6 tablets/24 hours.
Contraindications
Lactation. Children <12 yr.
Special Precautions
Porphyria, epilepsy, parkinsonism, history of depression, pregnancy. Renal or hepatic impairment. May impair ability to drive or operate machinery. Risk of acute hypersensitivity reactions in patients with phaeochromocytoma. Exclude the possibility of an underlying disorder if patient has persistent vomiting.
Adverse Reactions
Nausea, allergic reactions, skin rashes, acute renal tubular necrosis. Constipation or diarrhoea; drowsiness, headache, depression, lassitude, extrapyramidal reactions (especially if combined with phenothiazines); galactorrhoea; parkinsonism; neuroleptic malignant syndrome; tardive dyskinesia.
Potentially Fatal: Paracetamol: Very rare, blood dyscrasias (e.g. thrombocytopenia, leucopenia, neutropenia, agranulocytosis); liver damage. Metoclopramide: Very rarely, hypertensive crisis in patients with pheochromocytoma. Cardiac conduction disorders (IV admin).
Drug Interactions
Action of metoclopramide may be antagonised by anticholinergics and opioid analgesics. Metoclopramide may affect the absorption of orally administered drugs when given together.
ATC Classification
A03FA01 - metoclopramide ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.
N02BE01 - paracetamol ; Belongs to the class of anilide preparations. Used to relieve pain and fever.
Disclaimer: This information is independently developed by CIMS based on paracetamol + metoclopramide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in